Recent studies on leaflet thrombosis
| Author (year) (reference) | n | Detection method | Patients with thrombosis | THV | Duration |
| Latib et al 16 | 4266 | Echo, CT, histopathology | 26 (0.6%) eight asymptomatic (0.2%) | 20 of 2813 with Sapien/Sapien XT (0.7%) 6 of 1453 with CoreValve (0.4%) | 181 days (median) |
| Leetmaa et al 7 | 140 | CT | 5 (3.6%) four asymptomatic (2.9%) | Sapien XT | 91 days (median) |
| Makkar et al 3 | 55 | CT | 22 (40%) | 16 of 37 with Portico (43%) 6 of 14 with Sapein XT (43%) None of 4 with CoreValve (0%) | 30 days |
| Hansson et al 2 | 405 | CT | 28 (6.9%) 23 asymptomatic (5.7%) | Sapien XT or Sapien 3 | 1–3 months |
| Yanagisawa et al 4 | 70 | CT | 1 (1.4%) at discharge 7 (10%) at 6 months 10 (14.3%) at 1 year all asymptomatic | Sapien XT | Discharge 6 months 1 year |
| Chakravaty et al 14 | 752 | CT | 101 (13.4%) | 1 of 22 with Sapien (5%) 12 of 122 with Sapien XT (10%) 50 of 309 with Sapien 3 (16%) 3 of 70 with CoreValve (4%) 6 of 75 with CoreValve Evolut R (8%) 12 of 83 with Lotus (14%) 15 of 50 with Portico (30%) None of 6 with direct flow (0%) 1 of 7 with Centera (14%) 1 of 8 with Symetis (13%) | 58 days (median) |
| Pache et al 28 | 156 | CT | 16 (10.3%) all asymptomatic | Sapien 3 | 5 days (median) |
| Jose et al 17 | 642 | TEE, CT | 18 (2.8%) 10 asymptomatic (1.6%) | 9 of 121 with Sapien XT (7.4%) 4 of 160 with Sapien 3 (2.5%) 2 of 296 with CoreValve (0.67%) 1 of 6 with CoreValve Evolut R (16.7%) 2 of 56 with Lotus (3.6%) | 181 days (median) |
TEE, transesophageal echocardiography; THV, transcatheter heart valve.